SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status

Abstract

The Bcl-2 family of proteins is critical to the life and death of malignant B-lymphocytes. Interfering with their activity using small-molecule inhibitors (SMI) is being explored as a new therapeutic strategy for treating B-cell tumors. We evaluated the efficacy of TW-37, a non-peptidic SMI of Bcl-2 against a range spectrum of human B-cell lines, fresh patient samples and animal xenograft models. Multiple cytochemical and molecular approaches such as acridine orange/ethidium bromide assay for apoptosis, co-immunoprecipitation of complexes and western blot analysis, caspase luminescent activity assay and apoptotic DNA fragmentation assay were used to demonstrate the effect of TW-37 on different B-cell lines, patient derived samples, as well as in animal xenograft models. Nanomolar concentrations of TW-37 were able to induce apoptosis in both fresh samples and established cell lines with IC 50 in most cases of 165-320 nM. Apoptosis was independent of proliferative status or pathological classification of B-cell tumor. TW-37 was able to block Bim-Bcl-X L and Bim-Mcl-1 heterodimerization and induced apoptosis via activation of caspases -9, -3, PARP and DNA fragmentation. TW-37 administered to tumor-bearing SCID mice led to significant tumor growth inhibition (T/C), tumor growth delay (T-C) and Log 10 kill, when used at its maximum tolerated dose (40 mg/kg × 3 days) via tail vein. TW-37 failed to induce changes in the Bcl-2 proteins levels suggesting that assessment of baseline Bcl-2 family proteins can be used to predict response to the drug. These findings indicate activity of TW-37 across the spectrum of human Bcell tumors and support the concept of targeting the Bcl-2 system as a therapeutic strategy regardless of the stage of B-cell differentiation.

PNT2258, a novel deoxyribonucleic acid inhibitor, induces cell cycle arrest and apoptosis via a distinct mechanism of action: a new class of drug for non-Hodgkin's lymphoma

“…Our group has developed and evaluated different anti-BCL-2 strategies including small molecule inhibitors (SMIs) [20, 42–45] and anti-sense oligonucleotides [23, 27]. RNAi often requires large doses and continuous exposure for effective suppression of gene function.…”

Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas

“…19,20 Peripheral blood lymphocytes (PBL) were obtained from normal non-smoking healthy donors at Karmanos Cancer Institute. Primary antibodies for FOXO3a, p27, p21, p53, p73, Bax, b-actin and lamin were purchased from Cell Signaling (Danvers, MA, USA).…”

The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment

“…It has shown promise in inducing apoptosis and overcoming resistance in cases of B cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma. 120 Despite these many attempts to generate potent BH3 mimetics, none have proven as effective at binding the antiapoptotics as the BH3-only proteins themselves. Given the importance of the BH3 domain in the interaction between the pro-apoptotic proteins and the anti-apoptotics, Letai et al 25 generated synthetic peptides mimicking the different BH3-only proteins.…”